
Katherine Niederer Cahill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6486509/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature, 2018, 560, 649-654.	13.7	368
2	Prostaglandin D2: AÂdominant mediator of aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2015, 135, 245-252.	1.5	191
3	KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. New England Journal of Medicine, 2017, 376, 1911-1920.	13.9	159
4	Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2016, 137, 1566-1576.e5.	1.5	142
5	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S16-S116.	2.0	107
6	The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: AÂWork Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology, 2021, 147, 827-844.	1.5	69
7	A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1045-1047.	2.0	60
8	Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 831-840.	2.5	60
9	Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 537-545.	2.0	58
10	Impaired E Prostanoid ₂ Expression and Resistance to Prostaglandin E ₂ in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 34-40.	1.4	55
11	Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease. Journal of Allergy and Clinical Immunology, 2017, 139, 764-766.	1.5	42
12	Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 704-711.	2.5	42
13	Inflammatory heterogeneity in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2021, 147, 1318-1328.e5.	1.5	37
14	A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1174-1180.	2.0	35
15	Automated identification of an aspirin-exacerbated respiratory disease cohort. Journal of Allergy and Clinical Immunology, 2017, 139, 819-825.e6.	1.5	34
16	A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2019, 143, 316-324.e7.	1.5	34
17	Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 825-831.	2.0	31
18	Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 449-451.	2.0	29

#	Article	IF	CITATIONS
19	Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1647-1649.	2.0	24
20	Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2019, 143, 799-803.e2.	1.5	22
21	Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis. Current Allergy and Asthma Reports, 2015, 15, 69.	2.4	20
22	Eosinophilia-Associated Coronary Artery Vasospasm in Patients with Aspirin-Exacerbated Respiratory Disease. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1215-1219.	2.0	15
23	Pathogenesis of Aspirin-Induced Reactions in Aspirin-Exacerbated Respiratory Disease. Immunology and Allergy Clinics of North America, 2016, 36, 681-691.	0.7	14
24	DrugWAS: Drugâ€wide Association Studies for COVIDâ€19 Drug Repurposing. Clinical Pharmacology and Therapeutics, 2021, 110, 1537-1546.	2.3	13
25	Longitudinal progression of aspirinâ€exacerbated respiratory disease: analysis of a national insurance claims database. International Forum of Allergy and Rhinology, 2019, 9, 1420-1423.	1.5	12
26	Aspirin exacerbated respiratory disease: the search for a biomarker. Annals of Allergy, Asthma and Immunology, 2014, 113, 500-501.	0.5	11
27	Perimenstrual Asthma in Aspirin-Exacerbated Respiratory Disease. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 573-578.e4.	2.0	11
28	A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1338-1340.	2.0	10
29	Treatment practices for aspirinâ€exacerbated respiratory disease: analysis of a national insurance claims database. International Forum of Allergy and Rhinology, 2020, 10, 190-193.	1.5	10
30	Hearing loss and middle ear symptoms in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1671-1672.e3.	2.0	7
31	Immunologic effects of aspirin desensitization and high-dose aspirin therapy in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology, 2021, 148, 344-347.	1.5	7
32	Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1644-1645.e1.	2.0	7
33	Evaluating the glucagon-like peptide-1 receptor in managing asthma. Current Opinion in Allergy and Clinical Immunology, 2022, 22, 36-41.	1.1	5
34	Fevipiprant in CRSwNP and comorbid asthma: Wrong target population or wrong PGD2 receptor?. Journal of Allergy and Clinical Immunology, 2022, 149, 1587-1589.	1.5	5
35	Scoring tool for systemic symptoms during aspirin challenge detects mediator production in aspirin-exacerbated respiratory disease. Annals of Allergy, Asthma and Immunology, 2021, 127, 131-133.	0.5	4
36	Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index. Journal of Allergy and Clinical Immunology, 2022, 150, 170-177.e6.	1.5	4

#	Article	IF	CITATIONS
37	Systems Approaches to Treatment Response to Imatinib in Severe Asthma: A Pilot Study. Journal of Personalized Medicine, 2021, 11, 240.	1.1	3
38	Aspirin-Exacerbated Respiratory Disease: A Unique Case of Drug Hypersensitivity. Immunology and Allergy Clinics of North America, 2022, 42, 421-432.	0.7	2
39	Reduced EP2 Receptor Expression Accounts For Prostaglandin E2 Resistance In Nasal Polyp Fibroblasts From Patients With Aspirin Exacerbated Respiratory Disease; Possible Role For Histone Acetylation In Control Of EP2 Receptor Expression. Journal of Allergy and Clinical Immunology, 2014, 133, AB77.	1.5	1
40	Reply to Watchorn <i>et al.</i> : Asthma Exacerbations in Individuals on Glucagon-like Peptide-1 Receptor Agonists for Type 2 Diabetes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 924-925.	2.5	1
41	COVID-19 in a series of patients with aspirin-exacerbated respiratory disease. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2900-2903.	2.0	1
42	Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352. Diabetes Care, 2021, 44, e165-e166.	4.3	1
43	Objective validity of patientâ€reported symptoms in aspirinâ€exacerbated respiratory disease patients. Clinical and Experimental Allergy, 2022, 52, 348-351.	1.4	1
44	Liraglutide as a Prophylactic Treatment for Sepsis Induced Lung Inflammation and Edema. FASEB Journal, 2022, 36, .	0.2	0